RxDoctor Payments Data

Ahmad Tuffaha, MD

Nephrology · Kansas City, KSNPI 1770783318

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $15,314 of the $15,314 with a category attached, or 100.0%. Sanofi accounts for 60.5% of it on its own, with 2 other manufacturers making up the rest. Among nephrology clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,314in general payments, 2019–2025

Across 6 payments — averaging $2552.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$9K
  • Chiesi USA, Inc.$3K
  • Amicus Therapeutics, Inc.$3K
$13,550in research payments, 2019–2025

Across 10 payments — averaging $1355.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$14K

What the payments were for

  • Consulting fees$15,314100%

General payments by program year

20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi3$9,264
Chiesi USA, Inc.2$3,300
Amicus Therapeutics, Inc.1$2,750

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,314 in reported general payments places this provider in the 90th percentile of 55 nephrology providers in Kansas.

See all nephrology providers in Kansas

Medicare billing

Part B allowed, 2024
$177,172
Medicare patients
367
Services billed
1,515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FabrazymeAgalsidase Beta48$786,634
GalafoldMigalastat Hcl13$383,545
Potassium Chloride34$1,769
Metolazone22$453
Furosemide71$285
Losartan Potassium44$254
Clonidine Hcl12$209
Amlodipine Besylate41$200
Calcitriol23$187
Carvedilol37$168
Metoprolol Succinate12$167
Hydralazine Hcl11$154
Lisinopril26$130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiFabrazyme$9,264$786,63448 claims
Amicus Therapeutics, Inc.Galafold$2,750$383,54513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 55 nephrology providers in Kansas.

Other nephrology in Kansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →